Lisa M. Holle, PharmD, BCOP, FHOPA

Melphalan flufenamide (Pepaxto; Oncopeptides AB) in combination with dexamethasone was granted accelerated approval on February 26, 2021, by the FDA for adult patients with relapsed or refractory multiple myeloma.

Belantamab mafodotin-blmf is now indicated for adult patients with relapsed or refractory myeloma who have received at least 4 prior therapies.

On October 22, 2020, the FDA approved remdesivir (Veklury; Gilead) as the first treatment for coronavirus disease 2019 (COVID-19).

The FDA approved azacitidine tablets (Onureg; Celgene Corporation) on September 1, 2020

On May 8, 2020, the FDA granted accelerated approval to selpercatinib (Retevmo; Eli Lilly and Company).

First oral drug for advanced or metastatic bladder cancer.

Both responder and remitter patients experienced a statistically significant longer time to relapse with esketamine compared to the placebo

FDA approves apalutamide for castration-resistant prostate cancer.

Emicizumab-kxwh brings together factors IXa and X to restore the function of the missing activated factor VIII and the blood clotting process.

A new era of treatment has arrived-here’s what you need to know.

The New Drug Review for April